Angela Mae Obermiller, PharmD

Articles by Angela Mae Obermiller, PharmD

The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?

ByAngela Mae Obermiller, PharmD,Mehmet Sitki Copur, MD

March 15th 2011

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Latest Updated Articles

The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?
March 15th 2011

Trending on OncLive

T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer

Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant High-Grade Glioma

Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued

What Does the FDA Approval of Orally Disintegrating Nilotinib Tablets Mean for CML Practice?

Trial Data and Clinical Influences Shape Decision-Making Across the Breast Cancer Continuum